102 related articles for article (PubMed ID: 23449197)
1. Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.
Amada H; Asanuma H; Koami T; Okada A; Endo M; Ueda Y; Naruse T; Ikeda A
Chem Pharm Bull (Tokyo); 2013; 61(3):286-91. PubMed ID: 23449197
[TBL] [Abstract][Full Text] [Related]
2. Novel ALK5 inhibitor TP0427736 reduces TGF-β induced growth inhibition in human outer root sheath cells and elongates anagen phase in mouse hair follicles.
Naruse T; Aoki M; Fujimoto N; Arase S; Oura H; Ueda Y; Ikeda A
Pharmacol Rep; 2017 Jun; 69(3):485-491. PubMed ID: 28324846
[TBL] [Abstract][Full Text] [Related]
3. 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitors.
Amada H; Sekiguchi Y; Ono N; Koami T; Takayama T; Yabuuchi T; Katakai H; Ikeda A; Aoki M; Naruse T; Wada R; Nozoe A; Sato M
Bioorg Med Chem; 2012 Dec; 20(24):7128-38. PubMed ID: 23117174
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
[TBL] [Abstract][Full Text] [Related]
6. Role of ALK5/Smad2/3 and MEK1/ERK Signaling in Transforming Growth Factor Beta 1-modulated Growth, Collagen Turnover, and Differentiation of Stem Cells from Apical Papilla of Human Tooth.
Chang HH; Chang MC; Wu IH; Huang GF; Huang WL; Wang YL; Lee SY; Yeh CY; Guo MK; Chan CP; Hsien HC; Jeng JH
J Endod; 2015 Aug; 41(8):1272-80. PubMed ID: 26001858
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase.
Yakymovych I; Engström U; Grimsby S; Heldin CH; Souchelnytskyi S
Biochemistry; 2002 Sep; 41(36):11000-7. PubMed ID: 12206672
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.
Piao S; Choi MJ; Tumurbaatar M; Kim WJ; Jin HR; Shin SH; Tuvshintur B; Yin GN; Song JS; Kwon MH; Lee SJ; Han JY; Kim SJ; Ryu JK; Suh JK
J Sex Med; 2010 Oct; 7(10):3385-95. PubMed ID: 20233292
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.
Kim YW; Kim YK; Lee JY; Chang KT; Lee HJ; Kim DK; Sheen YY
Xenobiotica; 2008 Mar; 38(3):325-39. PubMed ID: 18274960
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.
Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P
Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-2 is a negative regulator of anti-proliferative function and signaling of transforming growth factor-β in endothelial cells.
Xie L; Vo-Ransdell C; Abel B; Willoughby C; Jang S; Sowa G
Am J Physiol Cell Physiol; 2011 Nov; 301(5):C1161-74. PubMed ID: 21832243
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).
Callahan JF; Burgess JL; Fornwald JA; Gaster LM; Harling JD; Harrington FP; Heer J; Kwon C; Lehr R; Mathur A; Olson BA; Weinstock J; Laping NJ
J Med Chem; 2002 Feb; 45(5):999-1001. PubMed ID: 11855979
[TBL] [Abstract][Full Text] [Related]
16. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis.
Petersen M; Thorikay M; Deckers M; van Dinther M; Grygielko ET; Gellibert F; de Gouville AC; Huet S; ten Dijke P; Laping NJ
Kidney Int; 2008 Mar; 73(6):705-15. PubMed ID: 18075500
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of transforming growth factor-beta signalling attenuates interleukin (IL)-18 plus IL-2-induced interstitial lung disease in mice.
Segawa S; Goto D; Yoshiga Y; Sugihara M; Hayashi T; Chino Y; Matsumoto I; Ito S; Sumida T
Clin Exp Immunol; 2010 Jun; 160(3):394-402. PubMed ID: 20089076
[TBL] [Abstract][Full Text] [Related]
19. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
20. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
